GSK-3862995

N/A

Report date: 2026/04/08 15:42:10

Base Information

Drug NameGSK-3862995
Drug Alias NameGSK3862995BGSK-3862995BGSK3862995GSK-3862995
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionAnti-Interleukin-33
TargetsInterleukin-33
Therapy Area/IndicationsPulmonary Disease, Chronic ObstructiveBronchiectasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermanyUnited Kingdom +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline PlcGlaxosmithkline Research & Development LtdGlaxosmithkline Manufacturing Spa +[4] 
Inactive CompaniesN/A
Active IndicationsPulmonary Disease, Chronic ObstructiveBronchiectasis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A